REGENXBIO stock
RGNXNASDAQREGENXBIO Inc., HealthcareISIN US75901B1070
34Score 34 out of 100, Weak
Price and trend
57 / 100
Price history
−31% in one yearThe chart shows daily closes over 11 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 9.7% below it.
Since September 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 66).
The price is 50% below its 52-week high. Largest decline in 11 years: 94% (July 2018 to April 2025).
Chart figures for advanced users
- SMA 50$7.69
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$8.90
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)66
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$5.65
- The lowest closing price of the last twelve months.
- Resistance$15.98
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- REGENXBIO Inc. belongs to the Biotechnology industry (United States) and, with a market value of $530.96M, is number 238 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $170.44M (up 104.5% year on year) and a loss of $193.88M.
- For fiscal 2026, analysts expect on average revenue of $151.29M (down 11.2%) and adjusted earnings per share of −$3.45.
Show more
- MEQIRI Score 34 out of 100 (Weak): rank 635 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- DilutionShare count up 38% since 2020.Capital allocation 18
- High debtDebt 2.54 times equity (fiscal 2025), Biotechnology median 0.09.Stability 31
- Loss-makingLoss of $175.23M over the last 12 months.Fundamentals 17
The score is held back by capital allocation and fundamentals.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 32 to 34.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 4.6% on the twelve months before. Revenue has grown strongly since 2013, at around 32% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 88%, operating −95%, net −114%. Last 12 months: net −100%.
Debt & balance sheet
Fiscal 2025Debt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 4 Mar 2027in 111 days
- Last reported
- 5 Nov 2026EPS reported −$0.62 (expected −$1.29)above expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 5.5% since 15 Oct 2026.
- Earnings per share
- −$3.45−2.7%
- Revenue
- $151.29M−6.0%
- Earnings per share
- −$2.74+5.5%
- Revenue
- $203.37M+2.5%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $949,381 in total. One insider sold, $718,232 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at REGENXBIO
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 34
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Adlai NortyeANL $558.4M36
- ValnevaVLA.PA $554.46M29
- Helus PharmaHELP $549.18M39
- Crescent BiopharmaCBIO $533.76M33
- Eupraxia PharmaceuticalsEPRX $525.16M44
- Egetis TherapeuticsEGTX.ST $518.45M42
- Phathom PharmaceuticalsPHAT $506.45M29
- DiaMedica TherapeuticsDMAC $503.13M46
ETFs that hold REGENXBIO
Held by 6 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Genomics & Biotechnology UCITS ETFGN0M | 0.30% | 0.50% | €127.64M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.03% | 0.40% | €1.5B |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.03% | 0.35% | €1.25B |
Show 3 more
| iShares Ageing Population UCITS ETF2B77 | 0.03% | 0.40% | €813.42M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.02% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.28B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 28 Feb 2023)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.